Chai Discovery Raises $70 Million in Series A to Advance AI-Powered Molecular Design for Next-Generation Therapeutics

Chai Discovery, an AI-driven company focused on predicting and reprogramming molecular interactions to accelerate the development of transformative therapeutics, has announced a $70 million Series A funding round. The investment was led by Menlo Ventures, including a contribution from their Anthology Fund—a strategic partnership with Anthropic aimed at identifying and supporting high-potential AI startups. Additional participation came from new investors Yosemite, DST Global Partners, SV Angel, Avenir, and DCVC. The capital will fuel Chai Discovery’s mission to harness artificial intelligence for breakthroughs in drug discovery and molecular design, enabling faster, more precise development of life-changing treatments.